The Monsanto company has forged a new partnership with Alnylam Pharmaceuticals, Inc., a biopharmaceutical company whose primary focus seems to be on figuring out how to best crack the genetic code so as to manipulate the way genes inherently express themselves.
And based on the
agreement the two companies have made publicly with one another, it
appears as though Monsanto is planning to utilize Alnylam's proprietary
gene-silencing technologies in its emerging agricultural pursuits,
which
will likely spawn a whole new category of problems for humanity and the
planet at large.
But
Monsanto is
an agricultural company, not a pharmaceutical company, which begs the
obvious question as to why this multinational company has suddenly
decided to shell out nearly
$30 million with promises of perpetual
royalty payments to gain access to this emerging technology.
As it turns
out, Monsanto has plans to roll out all sorts of new
genetically-modified (GM) crops, crop pesticides and herbicides, and
various other technologies with built-in RNAi modifications, which could
turn future GM food crops into "drugs."
No comments:
Post a Comment